Global X Defense Tech ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Defense Tech ETF trades at $69.49, while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $529.65 |
52-Week Low | $58.20 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $69.04, up 1.86% with bullish technical signals from moving averages but overbought RSI readings. The ETF benefits from institutional accumulation and positive sentiment around global defense spending increases. Recent news highlights multiple institutional investors increasing positions, while technical analysis shows strong support at $68 and resistance at $70.
Outlook remains positive given geopolitical tensions driving defense budgets higher, though overbought conditions suggest potential near-term consolidation. Key risks include political uncertainty and valuation concerns after recent gains. The ETF offers diversified exposure to defense technology with institutional confidence supporting the long-term thesis.
No Aura AI signal available yet.
Trailing returns across standard periods
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →